Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Mar;8(2):66-82.
doi: 10.1177/1756283X14558193.

Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases

Aurelien Amiot  1 , Laurent Peyrin-Biroulet  2
Affiliations
Review

Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases

Aurelien Amiot et al. Therap Adv Gastroenterol. 2015 Mar.

Abstract

Biological agents for inflammatory bowel diseases (IBD) targeting tumor necrosis factor (TNF) have changed the way to treat IBD refractory to standard medications and allowed us to reach new therapeutic goals such as mucosal healing and deep remission. A better understanding of the components of the pathological processes that are a hallmark of IBD has led to the development of a new family of biological agents in Crohn's disease and ulcerative colitis. Biosimilars, which are copy versions of currently licensed biological agents, will be soon available. The biosimilar of infliximab is as effective and as safe as its originator in rheumatologic conditions, while a new anti-TNF agent, namely golimumab, has been recently approved for refractory ulcerative colitis. Beyond TNF blockers, anti-adhesion molecules appear to be a potent drug class for IBD. Vedolizumab was recently approved for both Crohn's disease and ulcerative colitis. Numerous other compounds are in the pipeline. Ustekinumab looks very promising for Crohn's disease. Smad7 antisense oligonucleotide might enrich our armamentarium if preliminary data are confirmed in upcoming clinical trials. Herein, we review the efficacy and safety of new and emerging biological agents that are currently investigated in IBD clinical trials.

Keywords: Crohn’s disease; anti-TNF agents; biologics; inflammatory bowel diseases; ulcerative colitis.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: AA has received payment for lectures from Biocodex and MSD and travel accommodation from Abbvie, MSD and Biocodex. LP-B has received consulting fees from Merck, Abbott, Janssen, Genentech, Mitsubishi, Ferring, Norgine, Tillots, Vifor, Shire, Therakos, Pharmacosmos, Pilège, BMS, UCB-pharma, Hospira, Celltrion, Takeda, Boerhinger-Ingelheim and Lilly; and lecture fees from Merck, Abbott, Janssen, Ferring, Norgine, Tillots, Vifor, Therakos and HAC-pharma.

Figures

Figure 1.
Figure 1.
The therapeutic pipeline in Crohn’s disease. Drugs are categorized based on the mechanism of action. Purple symbols indicate oral drugs. rh, recombinant human; IL, interleukin; TNF, tumor necrosis factor.
Figure 2.
Figure 2.
The therapeutic pipeline in ulcerative colitis. Drugs are categorized based on the mechanism of action. Purple symbols indicate oral drugs. IL, interleukin; TNF, tumor necrosis factor.
See this image and copyright information in PMC

References

    1. Asthana A., Sparrow M., Peyrin-Biroulet L. (2014) Optimizing conventional medical therapies in inflammatory bowel disease. Cur Drug Targets September 14 [Epub ahead of print]. - PubMed
    1. Billioud V., Sandborn W., Peyrin-Biroulet L. (2011). Loss of response and need for adalimumab dose intensification in Crohn’s disease: a systematic review. Am J Gastroenterol 106: 674–684. - PubMed
    1. Beunk L., Verwoerd A., Van Overveld F., Rijkers G. (2013) Role of mast cells in mucosal diseases: current concepts and strategies for treatment. Expert Rev Clin Immunol 9: 53–63. - PubMed
    1. Burger D., Travis S. (2011) Conventional medical management of inflammatory bowel disease. Gastroenterology 140: 1827–1837 e1822. - PubMed
    1. Choy E., Hazleman B., Smith M., Moss K., Lisi L., Scott D., et al. (2002) Efficacy of a novel pegylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: a phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford) 41: 1133–1137. - PubMed